Association of PAI‐1 gene polymorphism with survival and chemotherapy‐related vascular toxicity in testicular cancer
Open Access
Abstract
BACKGROUND: High Plasminogen‐Activator Inhibitor 1 (PAI‐1) expression by tumors has been associated with poor prognosis in several cancer types, and high systemic PAI‐1 levels with increased thrombosis risk. The authors investigated whether the germline 4G/5G deletion/insertion polymorphism in the PAI‐1 promoter (rs1799889), which may influence PAI‐1 expression, is associated with survival and chemotherapy‐related vascular toxicity in testicular cancer (TC).METHODS: Data were collected on PAI‐1 4G/5G polymorphism, survival, venous thromboembolism (VTE), and coronary heart disease (CHD) for 324 non‐seminomatous TC patients treated with platinum‐based chemotherapy. Genotypes were compared regarding survival and disease outcome. VTE and CHD incidence were compared with adjustment for cardiovascular risk factors and prothrombotic gene polymorphisms of coagulation factors II/prothrombin (G20210A) and V (G1691A).RESULTS: The 4G/4G variant of PAI‐1 4G/5G polymorphism shows a higher prevalence of International Germ Cell Cancer Classification (IGCCC) poor prognosis compared with 4G/5G and 5G/5G (24% vs 8% and 15%; chi‐square P = .003). In addition, the 4G/4G variant shows reduced TC‐related survival with a hazard ratio of 2.69 (95% CI, 1.26‐5.73; P = .010) for TC‐related death (adjusted for IGCCC). This is related to an increased risk for refractory disease and early relapses (odds ratio, 3.35; 95% CI, 1.48‐7.59; P = .004). PAI‐1 4G/5G polymorphism is not associated with VTE and CHD risk.CONCLUSIONS: The 4G/4G variant of PAI‐1 4G/5G polymorphism may be an unfavorable prognostic as well as predictive factor for response to chemotherapy in TC patients. If confirmed, it may contribute to the identification of patients with increased risk for refractory disease. Cancer 2010. © 2010 American Cancer Society.Keywords
This publication has 42 references indexed in Scilit:
- Tumor-Derived Tissue FactorBearing Microparticles Are Associated With Venous Thromboembolic Events in MalignancyClinical Cancer Research, 2009
- Assessing Risk of Venous Thromboembolism in the Patient With CancerJournal of Clinical Oncology, 2009
- PAI-1 −675 4G/5G polymorphism as a prognostic biomarker in breast cancerBreast Cancer Research and Treatment, 2007
- Ten-year survival and risk of relapse for testicular cancer: A EUROCARE high resolution studyEuropean Journal of Cancer, 2007
- Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and venous thrombosisThrombosis and Haemostasis, 2007
- Prognostic Value of PAI1 in Invasive Breast Cancer: Evidence That Tumor-Specific Factors Are More Important Than Genetic Variation in Regulating PAI1 ExpressionCancer Epidemiology, Biomarkers & Prevention, 2006
- Long-Term Risk of Cardiovascular Disease in 5-Year Survivors of Testicular CancerJournal of Clinical Oncology, 2006
- Mutation in blood coagulation factor V associated with resistance to activated protein CNature, 1994
- Treatment of Disseminated Germ-Cell Tumors with Cisplatin, Bleomycin, and either Vinblastine or EtoposideNew England Journal of Medicine, 1987
- Increased Plasma Levels of a Rapid Inhibitor of Tissue Plasminogen Activator in Young Survivors of Myocardial InfarctionNew England Journal of Medicine, 1985